Ethinyl estradiol/norgestimate

Limits on what this shows

• Key negative/null findings: None located; this is a thin literature and the human study's magnitude could not be independently confirmed due to a tooling block (HTTP 429 on repeated attempts).
• At-risk subgroups: Not established in humans for this drug.
• Counter-evidence: The animal study used ethinyl estradiol alone (the shared estrogen component), not the norgestimate/ethinyl estradiol combination, and used doses/routes not necessarily comparable to oral contraceptive dosing in humans; this is disclosed rather than smoothed over. See Overlap map: this entry shares its primary mechanistic source with the Oxidative stress entry below.

Regulatory status

Not addressed in the label.

Population evidence

Chen, Li, Lavigne, Trush & Yager 1999 (PMID 10543024): rat liver mitochondria, hepatocytes, and HepG2 cells treated with ethinyl estradiol specifically (the estrogen component of this exact drug) showed increased mitochondrial superoxide production, studied in the context of EE as a hepatocarcinogen promoter. Jonderko et al. 2013 (PMID 23937278): a human study reporting that combined oral contraceptives affect liver mitochondrial activity (formulation not confirmed as norgestimate; full quantitative detail could not be retrieved, see access note).

Mechanism

Named for the animal data: ethinyl estradiol increases mitochondrial superoxide production in hepatocytes, a direct redox/electron-transport-chain effect of the estrogen component present in this drug.

Counter-evidence held on record

Animal, hepatocyte-specific data using the estrogen component alone; not shown in humans on this exact combination. Should surface, if at all, as a low-confidence research note, not a consumer-facing mitochondrial-harm claim.

Limits on what this shows

• Key negative/null findings: None of the human studies located were placebo-controlled non-use comparisons in norgestimate users specifically; several used other formulations or did not report progestin type.
• At-risk subgroups: Not established for this specific drug; athletes and smokers are the subgroups most studied in the OC-oxidative-stress literature generally.
• Counter-evidence: No source confirmed norgestimate specifically. See Overlap map: shares its mechanistic anchor with the Mitochondrial burden entry (Chen et al. 1999).

Regulatory status

Not addressed in the label.

Population evidence

Zal et al. 2012 (PMID 22494786): human study finding low-dose oral contraceptives enhanced lipid peroxidation, with vitamin E and C supplementation mitigating the effect. Kowalska & Milnerowicz 2016 (PMID 26921793): pro-/antioxidant status altered in young healthy women using OCs. Chen et al. 1999 (PMID 10543024): ethinyl-estradiol-specific rat liver mitochondrial superoxide increase (see Mitochondrial burden entry). Quinn et al. 2021/2022 (PMID 34106325, 35674828) studied blood oxidative stress biomarkers across the menstrual cycle in contraceptive users, with N-acetylcysteine supplementation studied as a mediator.

Mechanism

Estrogen-driven increase in reactive oxygen species generation (supported at the mechanistic level by the ethinyl-estradiol-specific animal data), plausibly compounded by the lower circulating antioxidant nutrient levels (vitamin C, alpha-tocopherol, CoQ10) noted elsewhere in this dossier.

Counter-evidence held on record

Modest, class-level, mixed-quality evidence. Should not be presented as a confirmed "oxidative damage" claim for this specific product.

Limits on what this shows

• Key negative/null findings: None located contradicting the direction; the finding is unusually consistent across decades, doses, and progestins, which is itself evidence the mechanism is estrogen-driven rather than progestin-specific.
• At-risk subgroups: Patients with unexplained elevated serum copper/ceruloplasmin being worked up for Wilson disease or hepatic disease should have OC use recorded, since it is a benign confounder for this specific lab pattern.
• Counter-evidence: No formulation-specific (norgestimate) study located; every source is class-level (Tier C) for this exact drug despite the mechanism plausibly applying to any ethinyl-estradiol-containing pill, including this one.

Regulatory status

Not addressed directly in the SPRINTEC label, but the label's own note that estrogen induces hepatic synthesis of several binding globulins (SHBG, CBG, TBG) is mechanistically consistent with induced ceruloplasmin (a copper-binding, copper-transport protein) synthesis.

Population evidence

Carruthers et al. 1966 (PMID 5919365, n=25) found a marked increase in serum copper and ceruloplasmin in OC users. Schenker et al. 1972 (PMID 4362283) and Horwitt et al. 1975 (PMID 1119436) replicated the correlation. Kamyab et al. 1980 (PMID 7391523, n=104 Iranian women, 3–108 months of combined-OC use) found duration-related variation. Garmizo & Frauens 2008 (PMID 18772711) is a case report of abnormally elevated serum copper and ceruloplasmin that normalized after stopping an estrogen-based OC.

Mechanism

Named: estrogen-driven induction of hepatic ceruloplasmin synthesis, the same class of hepatic protein-synthesis effect documented on the label for SHBG/CBG/TBG.

Counter-evidence held on record

This is a retention/excess-risk finding, not depletion. Copper supplementation should not be recommended on the basis of this drug, and this pattern should not itself trigger a Wilson disease workup without independent supporting findings.

Limits on what this shows

• Key negative/null findings: Frassinelli-Gunderson et al. found no major ferritin difference between users and non-users, a genuine null result recorded here per Step 5.
• At-risk subgroups: None identified for depletion; if unexplained anemia develops on this drug, evidence favors investigating causes other than the pill first (Hard Rule 6, confounding by indication).
• Counter-evidence: No formulation-specific (norgestimate) study located; the largest study (Milman 1992) is Danish, 1992, formulation unspecified.

Regulatory status

Not addressed in the label; reduced menstrual blood loss is a well-known secondary effect of combined OCs generally.

Population evidence

Milman, Kirchhoff & Jørgensen 1992 (PMID 1511065, n=1,359 Danish women) found OC users had higher serum ferritin and a lower frequency of iron deficiency. Larsson et al. 1992 (PMID 1486771) linked low-dose combined OC use to reduced menstrual blood loss and altered iron status. Frassinelli-Gunderson et al. 1985 (PMID 3984924, 46 users vs. 71 non-users) found no major difference in most iron-status parameters, with lower RBC count/hematocrit but hemoglobin not significantly affected. Gokkaya et al. 2025 (PMID 39738891) found paradoxically increased ferritin in PCOS patients on ethinyl estradiol/drospirenone (a different progestin) despite possible iron deficiency.

Mechanism

Indirect: combined OCs reduce endometrial proliferation and menstrual blood loss, sparing iron rather than affecting iron absorption, transport, or utilization directly. This is closer to a secondary consequence of the drug's intended pharmacologic effect than a direct nutrient-drug interaction (Hard Rule 2 caution applied: the underlying outcome, reduced menstrual bleeding, is not itself filed as a nutrient finding, only the measured ferritin/iron-status change is).

Counter-evidence held on record

This is a protective/retention direction. It is not license to add iron supplementation, and the common consumer claim that this drug class causes iron-deficiency anemia is contradicted by the direction of the evidence (see Fails Verification).

Limits on what this shows

• Key negative/null findings: Krog et al. 2022 (PMID 35553675) found menstrual cycle phase, not hormonal contraceptive use itself, was the stronger driver of microbiome changes across multiple body sites in their cohort — a genuine competing-explanation finding recorded here per Step 5.
• At-risk subgroups: PCOS patients are the most-studied subgroup, but PCOS itself is independently associated with microbiome alterations, so confounding by indication (Hard Rule 6) applies and is not excluded by the sources located.
• Counter-evidence: No formulation-specific (norgestimate) confirmation; the Krog et al. null/competing finding above.

Regulatory status

Not addressed in the label.

Population evidence

Hua et al. 2022 (PMID 35452382), described in search results as the first longitudinal human study of OC effects on gut microbiota. Clapp Organski et al. 2025 (PMID 40871620) found time- and intestinal-segment-dependent shifts in microbiota composition with estrogen and/or progesterone-containing contraceptives (appears to be an animal model based on "intestinal segment" sampling). Eyupoglu et al. 2020 (PMID 32860695) found altered gut microbiota, including increased Ruminococcaceae, in PCOS patients on OC therapy. Wydra et al. 2024 (PMID 39408349) is a systematic review of OC-microbiota effects in PCOS.

Mechanism

Proposed: estrogen exposure alters the "estrobolome" (gut bacterial species capable of deconjugating estrogens via beta-glucuronidase), creating a bidirectional interaction between the drug and microbiome composition; named at the class level but not confirmed mechanistically for this exact formulation.

Counter-evidence held on record

An emerging, genuinely mixed research area. Should not be presented as an established microbiome-harm claim for this product.

Limits on what this shows

• Key negative/null findings: None located specifically contradicting the CoQ10 finding; the Na-K-ATPase evidence is animal-only and formulation-unconfirmed.
• At-risk subgroups: Patients also on statins (which independently lower CoQ10 synthesis) may have compounded exposure; not established as clinically significant for this drug alone.
• Counter-evidence: No formulation-specific (norgestimate) confirmation; CoQ10 is not a classical vitamin/mineral and circulating levels are an imperfect proxy for tissue ATP-production capacity (flagged per Hard Rule 3).

Regulatory status

Not addressed in the label.

Population evidence

Palan, Magneson, Castillo, Dunne & Mikhail 2006 (PMID 16647895): human study reporting oral contraceptive use significantly decreased coenzyme Q10 and alpha-tocopherol (p<.001); full sample size and quantitative magnitude could not be retrieved due to a tooling block (HTTP 429), disclosed here rather than assumed. Palan et al. 2010 (PMID 20814444) compared EE bioavailability and related markers across oral, patch, and vaginal-ring delivery, finding oral contraceptives associated with lower EE bioavailability than the patch. Olatunji & Soladoye 2006 (PMID 17205706): rat model finding OC exposure altered cardiac and vascular Na+-K+-ATPase activity, with dietary calcium as an effect modifier.

Mechanism

Coenzyme Q10 is an obligate cofactor in mitochondrial electron transport chain complexes I-III and ATP synthesis; a significant reduction in circulating CoQ10 is mechanistically relevant to cellular ATP output, though circulating CoQ10 does not directly equal tissue CoQ10 status.

Counter-evidence held on record

Should surface only as a low-confidence monitoring prompt (e.g. for patients reporting fatigue), never as a confirmed "energy depletion" claim, and never paired with an unreviewed CoQ10 dose recommendation.

Limits on what this shows

• Key negative/null findings: Frassinelli-Gunderson et al.'s own finding that hemoglobin was unaffected is the key null result here, recorded per Step 5 rather than omitted.
• At-risk subgroups: Smokers (Kimelski 1986) show a different, confounded pattern (increased erythrocyte mass) not generalizable to non-smokers.
• Counter-evidence: No formulation-specific (norgestimate) confirmation. Per Hard Rule 2, this entry does not file the drug's intended reduction in menstrual blood loss itself as a nutrient/oxygen-delivery deficiency; only the directly measured hematologic parameters are graded.

Regulatory status

Not addressed in the label.

Population evidence

Frassinelli-Gunderson et al. 1985 (PMID 3984924, 46 users vs. 71 non-users) found significantly lower RBC count and hematocrit in OC users, but hemoglobin was not significantly affected. Milman et al. 1992 (PMID 1511065, n=1,359) found higher ferritin (opposite direction on the iron-store side; see Iron entry, overlap disclosed below). Kimelski 1986 (PMID 3521099) found increased circulatory erythrocyte mass specifically in smoking OC users, an effect confounded by smoking itself.

Mechanism

Not clearly established as a direct drug-oxygen-delivery mechanism; plausibly reflects plasma volume changes rather than a true reduction in oxygen-carrying capacity, since hemoglobin (the direct oxygen-carrying measure) was not significantly affected in the largest relevant source.

Counter-evidence held on record

Net signal is weak and, if anything, reassuring (stable hemoglobin, often higher ferritin). Should not be presented as an oxygen-delivery deficit.